Alport Syndrome clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 12 years and up
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
San Francisco, California and other locations
Our lead scientists for Alport Syndrome research studies include Meyeon Park, MD.